Literature DB >> 26437069

Exacerbation of IgA nephropathy following G-CSF administration for PBSC collection: suggestions for better donor screening.

J B L Lee1, A Billen2,3, R N Lown2,3, M N Potter4, C F Craddock2,5, H de Lavallade6, B E Shaw2,3,4, C C Sharpe1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26437069     DOI: 10.1038/bmt.2015.224

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

Review 1.  IgA nephropathy.

Authors:  Jonathan Barratt; John Feehally
Journal:  J Am Soc Nephrol       Date:  2005-06-01       Impact factor: 10.121

2.  Possible involvement of G-CSF in IgA nephropathy developing in an allogeneic peripheral blood SCT donor.

Authors:  Y Funakoshi; A Nazneen; Y Nakashima; K Nakashima; M Okada; T Taguchi; H Moriuchi
Journal:  Bone Marrow Transplant       Date:  2010-03-01       Impact factor: 5.483

3.  Acute glomerulonephritis in a donor as a side effect of allogeneic peripheral blood stem cell mobilization with granulocyte colony-stimulating factor.

Authors:  B Nasilowska-Adamska; A Perkowska-Ptasinska; A Tomaszewska; A Serwacka; B Marianska
Journal:  Int J Hematol       Date:  2010-12-01       Impact factor: 2.490

Review 4.  The incidence of primary glomerulonephritis worldwide: a systematic review of the literature.

Authors:  Anita McGrogan; Casper F M Franssen; Corinne S de Vries
Journal:  Nephrol Dial Transplant       Date:  2010-11-10       Impact factor: 5.992

Review 5.  Global evolutionary trend of the prevalence of primary glomerulonephritis over the past three decades.

Authors:  Keng-Thye Woo; Choong-Meng Chan; Yoke Mooi Chin; Hui-Lin Choong; Han-Kim Tan; Marjorie Foo; Vathsala Anantharaman; Grace S L Lee; Gilbert S C Chiang; Puay Hoon Tan; Cheng Hong Lim; Chorh Chuan Tan; Evan Lee; Hwee Boon Tan; Stephanie Fook-Chong; Yeow-Kok Lau; Kok-Seng Wong
Journal:  Nephron Clin Pract       Date:  2010-07-28

6.  Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Willis H Navarro; John E Levine; John P Miller; Bronwen E Shaw; Paul V O'Donnell; Navneet S Majhail; Dennis L Confer
Journal:  Blood       Date:  2014-04-15       Impact factor: 22.113

Review 7.  Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program.

Authors:  John P Miller; Elizabeth H Perry; Thomas H Price; Charles D Bolan; Chatchada Karanes; Theresa M Boyd; Pintip Chitphakdithai; Roberta J King
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

8.  Relapsing acute kidney injury associated with pegfilgrastim.

Authors:  Swati Arora; Arpit Bhargava; Katherine Jasnosz; Barbara Clark
Journal:  Case Rep Nephrol Urol       Date:  2012-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.